Compare GlobalFoundries Inc. Ordinary Shares (GFS) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance

GlobalFoundries Inc. Ordinary SharesTrade

Halozyme Therapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

GlobalFoundries Inc. Ordinary Shares vs Halozyme Therapeutics Inc. Common Stock — how do they compare? GlobalFoundries Inc. Ordinary Shares trades at $48.03 (market cap $27.51B), while Halozyme Therapeutics Inc. Common Stock trades at $111.12 (market cap $12.58B). The key difference: GlobalFoundries Inc. Ordinary Shares is far larger — about 2.2× Halozyme Therapeutics Inc. Common Stock's market cap, and GlobalFoundries Inc. Ordinary Shares pays a 0.97% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GlobalFoundries Inc. Ordinary Shares for 0 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.

	GFS	HALO
Market Cap	$27.51B	$12.58B
Volume	10,416,572	2,179,278
Sector	Technology	Health
52-Week High	$89.96	$115.22
52-Week Low	$32.24	$61.63
Typical Hold Time	0 Days	1 Days
Enterprise Value	$26.80B	$14.49B
Dividend Yield	0.97%	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GFS

47% Buy53% Sell

Avg holding period · 0 Days

HALO

No sentiment data available yet.

Top news

Latest headlines on both assets

GFS

GlobalFoundries secures $2B deal with TSMC to supply AI chip packaging components, expanding AI role beyond GPUs.24/7 Wall Street · 7 hours agoBullish GlobalFoundries launches FDX Fusion, a cutting-edge FD-SOI platform for Physical AI, starting production in 2028.GlobeNewsWire · 11 hours agoBullish GlobalFoundries shares rise 3% on $2B deal with TSMC to boost US advanced chip packaging.Proactive Investors · 1 day agoBullish View details →

HALO

View details →

About GlobalFoundries Inc. Ordinary Shares

GlobalFoundries is a semiconductor foundry that manufactures chips for other companies. Its technologies serve automotive, communications, industrial, and consumer markets.

About Halozyme Therapeutics Inc. Common Stock

Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.